Expression of chemokine receptor CCR5 in patients with type 2 diabetes;Ocena ekspresji receptora chemokinowego CCR5 u chorych na cukrzycȩ typu 2

Polski Merkuriusz Lekarski

Volumn 20, Issue 116, 2006, Pages 195-198

  Dytfeld, Joanna ^a   Bogdański, Paweł ^a,b   Pupek Musialik, Danuta ^a   Jagodziński, Pawet P ^a   Bryl, Wiesław ^a   Kujawa, Alicja ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Zakład Biochemii i Biologii Molekularnej ^*  (Poland)

Author keywords

Atherosclerosis; Chemokines; Diabetes; Inflammation

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RECEPTOR DENSITY; T LYMPHOCYTE;

ADULT; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CCR5; T-LYMPHOCYTES;

EID: 33644986750     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Baggiolini M., Dewald B., Moser B.: Human chemokines: an update. Ann. Rev. Immunol., 1997, 15, 675-705.
2. Bajetto A., Bonavia R., Barbero S. i wsp.: Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J. Neurochem., 2002, 82, 1311-1329.
3. Beckman J.A., Creager M.A., Libby P.: Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA, 2002, 287, 2570-2581.
4. 1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest., 1997, 100, 2552-2561.
5. Cameron M.J., Arreaza G.A., Grattan M. i wsp.: Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J. Immunol., 2000, 165, 1102-1110.
6. Chalifoux L.V., Simon M.A., Pauley D.R. i wsp.: Arteriopathy in macaques infected with simian immunodeficiency virus. Lab. Invest., 1992, 67, 338-349.
7. Cocchi F., DeVico A.L., Garzino-Demo A. i wsp.: Identification of RANTES, MIP-1 alpha, and MIP-1 β as the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995, 270, 1811-1815.
8. Creager M.A., Luscher T.F., Cosentino F. i wsp.: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 2003, 108, 1527-1532.
9. Duncan B.B., Schmidt M.I., Pankow J.S. i wsp.: Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes, 2003, 52, 1799-805.
10. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
11. Feskens E.J., Kromhout D.: Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J. Clin. Epidemiol., 1992, 45, 1327-1334.
12. Furuta T., Saito T., Ootaka T. i wsp.: The role of macrophages in diabetic glomerulosclerosis. Am. J. Kidney Dis., 1993, 21, 480-485.
13. Herlitz J., Karlson B.W., Lindqvist J. i wsp.: Rate and mode of death during five years of follow up among patients with acute chest pain with and without a history of diabetes mellitus. Diabet. Med., 1998, 15, 308-314.
14. Imperatore G., Hanson R.L., Pettitt D.J. i wsp.: Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes, 1998, 47, 821-830.
15. Kim J.A., Berliner J.A., Natarajan R.D i wsp.: Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes, 1994, 43, 1103-1107.
16. Lohmann T., Laue S., Nietzschmann U. i wsp.: Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes, 2002, 51, 2474-2480.
17. Mach F.: The role of chemokines in atherosclerosis. Curr. Atheroscler. Rep., 2001, 3, 243-251.
18. Mokdad A.M., Bowman B.A., Ford E.S. i wsp.: The continuing epidemics of obesity and diabetes in the United States. JAMA, 2001, 286, 1195-200.
19. Moreno P.R., Fuster V.: New aspects in the pathogenesis of diabetic atherothrombosis. J. Am. Coll. Cardiol., 2004, 44, 2293-300.
20. Mueller A., Mahmoud N.G., Goedecke M.C. i wsp.: Pharmacological characterization of the chemokine receptor, CCR5. Br. J. Pharmacol., 2002, 135, 1033-1043.
21. Mueller A., Strange P.G.: The chemokine receptor, CCR5. Int. J. Biochem. Cell. Biol., 2004, 36, 35-38.
22. Nakajima K., Tanaka Y., Nomiyama T. i wsp.: Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes, 2002, 51, 238-242.
23. Nakajima K., Tanaka Y., Nomiyama T. i wsp.: RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care, 2003, 26, 892-898.
24. Onuffer J.J., Horuk R.: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol. Sci., 2002, 23, 459-467.
25. Ross R.: Atherosclerosis - an inflammatory disease. N. Eng. J. Med., 1999, 340, 115-126.
26. Scheeler A.D., Calderon T.M., Berman A.B. i wsp.: Human vascular smooth muscle cells possess functional CCR5. J. Biol. Chem., 2000, 275, 5466-5471.
27. Schwarz M., Radeke H.H., Resch K. i wsp.: Lymphocyte-derived cytokines induce sequential expression of monocyte- and T cell-specific chemokines in human mesangial cells. Kidney Int., 1997, 52, 1521-1531.
28. Shanmugam N., Reddy M.A., Guha M. i wsp.: High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes, 2003, 52, 1256-1264.
29. Terkeltaub R., Boisvert W.A., Curtiss L.K.: Chemokines and atherosclerosis. Curr. Opin. Lipidol., 1998, 9, 397-405.
30. Tsimanis A., Kalinkovich A., Bentwich Z.: Soluble chemokine CCR5 receptor is present in human plasma. Immunol. Lett., 2005, 96, 55-61.